"O L2iP Instituto de Pesquisas Clínicas foi projetado sob altos padrões de qualidade nacionais e internacionais para condução de estudos multicêntricos. Este centro de pesquisa clínica surgiu do entendimento que a região Centro-Oeste necessitava de um serviço profissionalizado na condução de estudos clínicos e teve suas atividades iniciadas em 2015. O Instituto está localizado dentro de um complexo hospitalar amplo e moderno para proporcionar atendimento médico com excelência. Nosso trabalho é dedicado ao avanço da medicina que traga benefício para o ser humano e acredita que as pesquisas clínicas são diretamente responsáveis pela melhoria contínua na qualidade de vida das pessoas."

During the past decade, L2IP - Instituto de Pesquisas Clínicas conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 2 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "L2IP - Instituto de Pesquisas Clínicas" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Janssen Vaccines & Prevention B.V." with 1 trials sponsored and "Kowa Research Institute, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "L2IP - Instituto de Pesquisas Clínicas" #1 collaborator was "Atea Pharmaceuticals, Inc." with 2 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "L2IP - Instituto de Pesquisas Clínicas" are "Crohn's Disease" (3 trials), "Depressive Disorder, Major" (3 trials), "Anhedonia" (2 trials), "COVID-19" (2 trials) and "Crohn Disease" (1 trials). Many other conditions were trialed in "L2IP - Instituto de Pesquisas Clínicas" in a lesser frequency.

Most popular intervention types in "L2IP - Instituto de Pesquisas Clínicas" are "Drug" (12 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Aticaprant" (3 trials), "Guselkumab" (2 trials), "Mirikizumab" (2 trials) and "Ustekinumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "L2IP - Instituto de Pesquisas Clínicas" are 14 trials for "All" genders.

Currently, there are NaN active trials in "L2IP - Instituto de Pesquisas Clínicas". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in L2IP - Instituto de Pesquisas Clínicas, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in L2IP - Instituto de Pesquisas Clínicas, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".